Tedor Announces New Regional Business Development Director

Article

Frank Sorce will be taking on the role of regional business development director for Tedor Pharma.

Tedor Pharma, a contract development and manufacturing organization based in Cumberland, RI, announced on Jan. 20, 2020 that Frank Sorce will be taking on the role of regional business development director for the company.

Prior to his new position, Sorce began his 30-year career in pharmaceutical sales at Merck Sharpe & Dohme and went on to hold senior sales leadership positions at Reliant Pharmaceuticals, Syneos Health, and UPM Pharmaceuticals, according to a company press release.

“Frank has a proven track record and we are excited to welcome him to the Tedor team as we continue to build on our 2019 successes,” said Doug Drysdale, president and CEO of Tedor.

Source: Tedor

 

 

Recent Videos
Lee Cronin, founder and CEO of Chemify
Nicole Hunter, head of Global WMArchitect at Watson-Marlow Fluid Technology Solutions
Related Content
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Roche Launches Mass Spectrometry Analyzer

Feliza Mirasol
December 25th 2024
Article

With the launch of its cobas mass spectrometry solution, Roche brings fully automated mass spec analysis to the clinical lab.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Scinai Immunotherapeutics Forms CDMO Subsidiary in US

Feliza Mirasol
December 18th 2024
Article

The company has formed Scinai Bioservices Inc., new US-based subsidiary operating out of Delaware that will serve biotech companies in early stage drug development.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Novo Nordisk Invests DKK 8.5 Billion to Build New Manufacturing Facility for Rare Disease Therapies in Denmark

Feliza Mirasol
December 16th 2024
Article

With the DKK 8.5 billion (US$1.2 billion) investment, Novo Nordisk will build a new modular and flexible production facility in Odense, Denmark, to produce multiple products for rare diseases.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Intertek and CrystecPharma Partner to Advance Formulation and Development of Dry Powder Inhaler Products

Feliza Mirasol
December 12th 2024
Article

The companies will develop a platform that can enable rapid development of DPI products.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Novo Nordisk to Acquire Manufacturing Sites Upon Catalent Acquisition and Acquires Novavax’s Czech Republic Site

Feliza Mirasol
December 10th 2024
Article

The European Commission’s approval of the Catalent acquisition by Novo Holdings includes the related acquisition of three manufacturing sites by Novo Nordisk, which is also acquiring the Czech Republic manufacturing site of Novavax for $200 million.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Cellipont Bioservices and Xiogenix Partner on Advanced Filling Systems

Susan Haigney
December 10th 2024
Article

Cellipont Bioservices and Xiogenix Partner on Advanced Filling Systems The companies will offer Cellipont’s clients access to Xiogenix’ fill/finish system for cell therapy production.

© 2025 MJH Life Sciences

All rights reserved.